BJDX

Bluejay Diagnostics, Inc. (BJDX) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Bluejay Diagnostics, Inc. is a medical diagnostics company developing the Symphony platform, a rapid, near-patient test system for critical care settings, specifically targeting sepsis via an IL-6 immunoassay. The Company is an Emerging Growth Company and Smaller Reporting Company. As of June 30, 2026, the Company had completed patient enrollment for its SYMON-II pivotal clinical study and is progressing toward analytical and clinical validation to support a planned FDA 510(k) submission in the first half of 2027.

Key Financial Metrics

Note: The Company has no revenue as it has not yet received regulatory clearance for its products.

Material Changes vs. Prior Period

• Financing Activity: The Company raised approximately $8.5 million in gross proceeds from a June 2026 private placement (pre-funded warrants and Series G/H warrants) and $125,000 from a March 2026 private placement to insiders. This significantly increased cash reserves compared to the prior year.
• Operating Expenses: Total operating expenses increased to $4.29 million for the six months ended June 30, 2026, from $3.87 million in the prior year period. Research and Development (R&D) expenses rose by approximately $575,000, driven by increased clinical development costs. General and Administrative (G&A) expenses decreased slightly due to lower legal and accounting fees.
• Capital Structure: A 1-for-4 reverse stock split was effected on January 29, 2026. The Company also received shareholder approval for an additional potential reverse stock split (up to 1-for-20) to maintain Nasdaq compliance.
• Cash Position: Cash and cash equivalents increased by approximately $4.4 million during the period, primarily due to financing activities, offsetting the negative cash flow from operations.

Guidance, Outlook, Risks, and Contingencies

• Capital Requirements: Management expects to need to raise between $10.0 million and $14.0 million of additional capital by the end of fiscal year 2027 to fund commercialization and manufacturing scale-up.
• Going Concern: The Company has incurred net losses since inception and has an accumulated deficit of approximately $45.8 million. While current cash resources are estimated to fund operations through the second quarter of 2027, the Company states that these conditions raise substantial doubt about its ability to continue as a going concern without additional financing.
• Regulatory Timeline: The Company aims to complete analytical and clinical testing of SYMON-II samples by the end of 2026, with a goal of submitting a 510(k) application to the FDA in the first half of 2027.
• Nasdaq Listing Risks: The Company faces risks regarding Nasdaq listing requirements, specifically the $1.00 minimum bid price and a proposed $5 million minimum market value rule. The stock closed at $1.07 on August 7, 2026.
• Manufacturing: The Company relies on contract manufacturers (Sanyoseiko and Argonaut) for production. Delays in supply or validation could impact the regulatory submission timeline.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $9.6 million cash balance to fund operations through Q2 2027 given the projected need for $10M-$14M in additional capital.
• Regulatory Milestones: Monitor the completion of SYMON-II data analysis and the timing of the anticipated 510(k) submission in 2027.
• Dilution Risk: Review the terms of the June 2026 private placement, which included significant issuance of pre-funded warrants and Series G/H warrants, and the potential for further dilution in future fundraising.
• Nasdaq Compliance: Track the stock price relative to the $1.00 minimum bid requirement and the status of the proposed $5 million market value listing rule.
• Manufacturing Validation: Confirm progress on the transfer of manufacturing technology to Sanyoseiko and Argonaut to ensure readiness for commercial scale-up.